Search review questions

Functional outcome (Constant score from 0‐100, 100 is best) · people with impingement syndrome without full‐thickness rotator cuff tears

Global assessment of treatment success · people with impingement syndrome without full‐thickness rotator cuff tears

Health‐related quality of life (scale from −0.59 to 1, 1 is perfect health) · people with impingement syndrome without full‐thickness rotator cuff tears

Adverse events · people with impingement syndrome without full‐thickness rotator cuff tears

Serious adverse events · people with impingement syndrome without full‐thickness rotator cuff tears

Paina (scale from: 0‐10, 0 is no pain) · people with impingement syndrome without full‐thickness rotator cuff tears

Functional outcomee (scale from 0‐100, 100 is best) · people with impingement syndrome without full‐thickness rotator cuff tears

Global assessment of treatment success · people with impingement syndrome without full‐thickness rotator cuff tears

Fractures · individuals with osteoporotic vertebral fracture

Falls · individuals with osteoporotic vertebral fracture

Pain Scale: VAS (0 to 10), pain subscale of Functional Status Index (0 to 10) Higher score indicates greater pain levels · individuals with osteoporotic vertebral fracture

Physical performance: performance‐based measures TUG test · individuals with osteoporotic vertebral fracture

Physical performance: self‐report questionnaires Physical function subscale from the QUALEFFO‐41 Scale from 0 to 100 Lower scores indicate better physical function · individuals with osteoporotic vertebral fracture

Disease‐specific quality of life QUALEFFO‐41 total score Scale from 0 to 100 Lower scores indicate better quality of life · individuals with osteoporotic vertebral fracture

Adverse events · individuals with osteoporotic vertebral fracture

Disease activity score · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion participants that switched to another biologic due to loss of response ‐ not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Disease activity score · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion of participants with persistent remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion of participants switched to another biologic due to loss of response · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion of participants with persistent remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Withdrawals due to adverse events ‐ not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion of participants switched to another biologic · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Disease activity score ‐ · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Proportion of participants with persistent remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Physical function · adults with ankylosing spondylitis

Patient global assessment of disease activity · adults with ankylosing spondylitis

Spinal mobility · adults with ankylosing spondylitis

Fatigue · adults with ankylosing spondylitis

Adverse effects associated with exercises Exercise programme duration: range 3 to 24 weeks · adults with ankylosing spondylitis

Adverse events Exercise programme duration: range 3 to 24 weeks · adults with ankylosing spondylitis

Pain · adults with ankylosing spondylitis

Patient global assessment of disease activity · adults with ankylosing spondylitis

Spinal mobility · adults with ankylosing spondylitis

Fatigue · adults with ankylosing spondylitis

Adverse effects associated with exercises Exercise programme duration: range 3 to 24 weeks · adults with ankylosing spondylitis

Withdrawals because of adverse events Exercise programme duration: range 3 to 24 weeks · adults with ankylosing spondylitis

Physical function · adults with ankylosing spondylitis

Pain · adults with ankylosing spondylitis